<< Exhibitor
<< Press release
With just two weeks to go, anticipation is building for the 22nd China International In Vitro Diagnostic Expo by CACLP, the largest and most influential gathering of the IVD industry in China! Taking place 22-24 March 2025, at the Hangzhou Grand Convention & Exhibition Center, CACLP 2025 promises to be a world-class showcase of the latest innovations, professional networking and business opportunities.
The 7th China IVD Distribution Enterprise Forum is set to take place on 23 March 2025, at the Hangzhou Grand Convention and Exhibition Center.
As China’s in vitro diagnostic (IVD) industry continues its rapid development, numerous outstanding enterprises have made remarkable achievements in research and development, production, and market expansion.
Welcome to the 22nd China International In Vitro Diagnostic Expo by CACLP & 5th China IVD Supply Chain Expo!
The 1st National Primary Healthcare Laboratory Forum is a key event focused on strengthening primary healthcare laboratory testing, which plays a vital role in early disease diagnosis and treatment outcomes.
As China’s pet market continues to flourish, with rising pet ownership and increasing per capita spending, the demand for quality veterinary care is rapidly growing.
The 10th China Experimental Medicine Conference is set to take place on 21-23 March 2025, at the Hangzhou Grand Convention and Exhibition Center.
The 5th China Key Raw Material & Parts Forum is set to take place on 21 March 2025, at the Hangzhou Grand Convention and Exhibition Center.
The 12th China IVD Industry Development Conference is set to take place on 22-23 March 2025, at the Hangzhou Grand Convention and Exhibition Center.
The 22nd China International In Vitro Diagnostic Expo by CACLP will take place from 22-24 March 2025 at the Hangzhou Grand Convention & Exhibition Center in Hangzhou, China, alongside a range of concurrent activities starting from 21 March to enhance the overall event experience.
<< Industry news
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further strengthening its syndromic testing portfolio in the United States.
Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN’s serological infection diagnostics portfolio with validation for dried blood spots (DBS) as sample material in addition to serum and plasma.
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended December 31, 2024.
Dutch diagnostics firm MRC Holland said Friday that two of its blood-based assays for spinal muscular atrophy (SMA) have been certified under Europe's In Vitro Diagnostic Regulation (IVDR).
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business highlights.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2024.
CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2024.
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.68 billion for the first quarter ended Jan. 31, 2025, representing growth of 1.4% reported and up 1.2% core(1) compared to the first quarter of 2024.
BioMérieux announced Tuesday that its multiplex Biofire Spotfire Respiratory/Sore Throat Panel has received Health Canada approval.
Systemic lupus erythematosus (SLE) is the most common systemic autoimmune disease in China, with an incidence of 30.13–70.41/100000 population. The kidney is the most commonly involved organ in SLE, and 40% ~ 60% of SLE patients have lupus nephritis (LN).
<< Video showcase
International Laboratory Medicine and In Vitro Diagnostic Forum
The 11th China IVD Industry Development Conference (CIIDC)
The 9th China Experimental Medicine Conference (CEMC)
CACLP 2024 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
CACLP APP is available for download now!
Gentian at CACLP 2023 Onsite
in.vent Diagnostics at CACLP 2023 Onsite
Charming Group at CACLP 2023 Onsite
Dialab at CACLP 2023 Onsite
JTC at CACLP 2023 Onsite
Certest at CACLP 2023 Onsite
Yashraj Biotechnology at CACLP 2023 Onsite
Magtivio at CACLP 2023 Onsite
The 8th China Experimental Medicine Conference (CEMC)
The 10th China IVD Industry Development Conference (CIIDC)
CACLP 2023 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
CACLP's new website is launching!
Autobio on Medlab Middle East 2023
EasyDiagnosis on Medlab Middle East 2023
BioPerfectus on Medlab Middle East 2023
<< Download centre
CACLP 2025 Exhibitor Manual
CACLP 2025 Floor Plan
CACLP 2025 Full Schedule
CACLP & CISCE 2024 Draw Global Attention to Innovations and Collaborations in IVD Industry
CACLP & CISCE to present the latest in IVD with 1300+ Exhibitors and 100+ Concurrent Activities this March in Chongqing.pdf
CACLP & CISCE 2024 - Floor Plan
CACLP & CISCE 2024 - Exhibitor Manual
1200+ Global Exhibitors Confirmed Their Participation on the 21st CACLP and 4th CISCE in Chongqing, March 2024
CACLP & CISCE 2023 Post-show Report
Over 1,100 Exhibitors Commit to Attend the 2024 China Association of Clinical Laboratory Practice Expo (CACLP) and China IVD Supply Chain Expo (CISCE)
Copyright © 2025 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.
Go back
